RECENT NEWS

French rapid test manufacturer Biosynex and Chembio Diagnostics, point-of-care diagnostics company focused on infectious diseases, have announced that the companies are to merge.

Groves Medical Group has started offering Stockholm3 for prostate cancer testing. This is the first UK clinic that uses Stockholm3.

The CFX Opus Deepwell Dx Real-Time PCR System is the latest addition to the Bio-Rad portfolio of real-time PCR instruments. The system offers accurate and precise quantification with flexibility for reactions up to 125 µl in a 96-well format for quantitative PCR (qPCR) diagnostic assays. The CFX Opus Dx Real-Time PCR System is also available in a 96- and 384-well reaction block format.

Pangaea Data, which provides a novel AI-driven product for characterising patients by mapping their journeys and disease trajectories in a privacy-preserving and scalable manner, has announced that it has been named ‘Digital Solution of the Year’ by the UK Government’s Department for International Trade (DIT), as part of its 2023 UK Life Science Innovator Showcase.

Medical diagnostics company Cytovale’s IntelliSep test has received US Food and Drug Administration (FDA) 510(k) clearance to aid in the early detection of sepsis.

This year will be pivotal for many diagnostic companies as they try to navigate the ongoing supply chain issues and the upcoming recession, says GlobalData, a leading data and analytics company.

SmartControl EM from Microgenetics is purpose-built environmental monitoring software that saves time, improves compliance, and empowers quality managers to make better decisions.

Registration is now open for the British Society for Microbial Technology (BSMT) 38th Annual Microbiology Conference, with early bird booking rates available until 10 April.

UK Biocentre is to partner with Eurofins, the world leader in biological testing, to provide high throughput research and clinical genomic services.

Cherwell, a specialist company in cleanroom microbiology solutions has published an update to its guide to ‘Environmental Monitoring Processes and Validation’, incorporating specific detail on the new version of EU GMP Annex 1. This aims to help sterile medicinal product manufacturers with reviewing and improving their environmental monitoring (EM) programs in preparation for compliance with the revised guidelines by August 2023.

Ibex Medical Analytics has announced a new agreement with AstraZeneca and Daiichi Sankyo, for the development, clinical validation and early adoption of an AI-powered product to aid pathologists with an accurate and reproducible assessment of HER2 immunohistochemistry (IHC) scoring in breast cancer patients.

LumiraDx has published the findings from its first annual UK survey, ‘Point of Care Diagnostics: A Clinician's View’, designed to understand clinician perspectives on the latest point of care technologies available.

The University of Derby has been awarded £5.8 million from the Office for Students (OfS) to develop a new biomedical science ‘Super Lab’.

VisualDx, an award-winning web-based clinical decision support system, has received a grant from the Bill & Melinda Gates Foundation to develop diagnostic and surveillance tools to help medical providers improve treatment decisions and outcomes in underserved areas.

Medical Air Technology (MAT), has just completed a turnkey design-and-build project to provide three new Containment Level 3 (CL3) laboratory suites at the University of Warwick.

Qiagen has announced the launch of EZ2 Connect MDx for use in diagnostic laboratories, making the IVD platform for automated sample processing available for widescale use 18 months after being made available for research.

Beckman Coulter Life Sciences has officially opened the first phase of its new $10 million research and development hub based in Loveland, Colorado, USA.

BD has introduced a new, robotic track system for its Kiestra microbiology laboratory solution that automates specimen processing, which can help to reduce manual labour and speed up results.

Vésale Bioscience is to receive €1.8M in grants from the European Innovation Council (EIC) Accelerator Fund for its PhageDiag project, a phagogram using artificial intelligence that enables decentralised diagnostics and personalised treatment.

Digital pathology provider Proscia has been chosen by the Netherlands Cancer Institute (NKI), one of the top 10 comprehensive cancer centres in Europe, to deploy its Concentriq Dx platform. NKI is transitioning to Concentriq Dx to expand its digital pathology practice, laying the foundation for its pathologists to deliver personalised diagnoses that better inform treatment decisions.